Andrea Venturini, MD
Pulmonary Disease · Satellite Beach, FLNPI 1194919720
Payments from drug & device makers
Across 128 payments — averaging $37.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Veran Medical Technologies, Inc.$1K
- Boehringer Ingelheim$405
- Electromed, Inc.$278
- AstraZeneca$238
- United Therapeutics Corporation$224
- Insmed, Inc.$215
- plus $2K from 29 others
What the payments were for
- Travel & lodging$1,16924%
- Food & beverage$3,64876%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Veran Medical Technologies, Inc. | 5 | $1,423 |
| Boehringer Ingelheim | 19 | $405 |
| Electromed, Inc. | 24 | $278 |
| AstraZeneca(2 entities) | 5 | $238 |
| United Therapeutics Corporation | 6 | $224 |
| Insmed, Inc. | 5 | $215 |
| Regeneron Healthcare Solutions, Inc. | 5 | $194 |
| Medtronic | 1 | $165 |
| Stryker | 2 | $161 |
| Pulmonx Corporation | 2 | $159 |
| Johnson & Johnson | 1 | $141 |
| GSK | 7 | $140 |
| Intuitive Surgical | 1 | $118 |
| Edwards Lifesciences | 1 | $102 |
| Sanofi | 4 | $83 |
| Mylan Specialty L.p. | 4 | $70 |
| Harmony Biosciences LLC | 4 | $65 |
| Covidien LP | 1 | $64 |
| ANI Pharmaceuticals, Inc. | 2 | $60 |
| Grifols USA, LLC | 4 | $60 |
| Amgen | 3 | $59 |
| Sunovion Pharmaceuticals Inc. | 4 | $55 |
| AbbVie | 2 | $45 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $41 |
| Novartis | 3 | $41 |
| Dendreon Pharmaceuticals LLC | 1 | $33 |
| Lilly USA, LLC | 1 | $29 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $26 |
| Portola Pharmaceuticals, LLC | 2 | $24 |
| Viatris Specialty LLC | 1 | $21 |
| Baxter Healthcare | 1 | $20 |
| Resmed Corp | 1 | $19 |
| Actelion Pharmaceuticals US, Inc. | 1 | $15 |
| Jazz Pharmaceuticals Inc. | 1 | $13 |
| Pfizer | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Spin$1,309
- SYMPLICITY G3$165
- Monarch Platform$141
- Arikayce$133
- CHARTIS CATHETER$129
- ZEPHYR DELIVERY CATHETER$129
- ZEPHYR ENDOBRONCHIAL VALVE$129
- PULMONX CHARTIS TABLET CONSOLE$129
- DUPIXENT$122
- Da Vinci Surgical System$118
- FlowTriever$114
- TEZSPIRE$104
- EV1000 Clinical Platform$102
How this compares
$4,817 in reported general payments places this provider in the 50th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tyvaso DpiTreprostinil | 14 | $327,905 |
| OfevNintedanib Esylate | 19 | $266,734 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 292 | $203,964 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 125 | $69,057 |
| Breo ElliptaFluticasone/Vilanterol | 68 | $29,754 |
| Spiriva RespimatTiotropium Bromide | 21 | $16,516 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $8,282 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $6,332 |
| BreynaBudesonide/Formoterol Fumarate | 20 | $4,286 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 11 | $3,504 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 87 | $2,881 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 11 | $2,333 |
| Ventolin HfaAlbuterol Sulfate | 14 | $1,529 |
| Montelukast Sodium | 84 | $1,142 |
| Azelastine Hcl | 31 | $1,005 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $140 | $302,775485 claims |
| Boehringer IngelheimOfev, Spiriva Respimat | $405 | $283,25040 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $238 | $14,61528 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Satellite Beach
- James KrainsonMiami$11.7M
- Jose DiazLeesburg$11.2M
- Carlos MartinezHomestead$9.2M
- Leonard DunnDunedin$7.6M
- Francis AverillClearwater$6.3M
- Charles BurgerJacksonville$5.6M
- Daniel LorchBrandon$5.5M
- Lourdes BoschMiami$4.2M
- Raj KarunakaraOcala$4M
- Neal WarshoffLoxahatchee$3.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.